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1. Introduction 
The idiopathic inflammatory myopathies (IIM), classically dermatomyositis (DM), 
polymyositis (PM), and inclusion body myositis (IBM), are acquired systemic autoimmune 
disorders defined by chronic muscle weakness and inflammation of unknown aetiology. 
The combination of clinical, laboratory, electromyographic, and histological features is the 
basis of diagnosis, as well as exclusion of several mimicking conditions (Bohan & Peter, 
1975; Dalakas & Hohlfeld, 2003; Mann et al, 2010; Mastaglia & Phillips, 2002). IIM are the 
most common causes of acquired muscle disease in adults, but are still rare conditions with 
an estimated overall prevalence of 50 to 100 cases per million (Oddis et al., 1990; Prieto & 
Grau 2010; Wilson et al., 2008). 
In recent years, taking into account additional clinical, immunological and histological 
features, new phenotypes among IIM, such as antisynthetase syndrome, autoimmune 
necrotizing myopathy, connective tissue disorder-associated myositis, or cancer-associated 
myositis (CAM), have been described (Cox et al., 2010; Dalakas, 2010; Dimachkie, 2011; 
Rider & Miller, 2011; Targoff, 2008). 
The association between cancer and IIM has been widely reported in the medical literature, 
particularly in DM patients (Buchbinder et al., 2001; Sigurgeirsson et al., 1992). Cancer 
screening is a common practice in patients recently diagnosed with IIM, but there is not 
consensus about how, and how often screening should be performed. The aim of this 
chapter is to describe the epidemiological, clinical, laboratory, and histological reported 
features about CAM, to analyze the current potentially approach to preclude malignancy in 
IIM, and to provide an advisable algorithm in the diagnosis of occult cancer in myositis. 
2. Background 
The association between IIM and malignancy has been appreciated for nearly a century. 
From the first case reports in 1916 (Kankeleit, 1916; Stertz, 1916), large, retrospective studies 
and reviews examining this association have been subsequently published (Airio et al., 1995; 
Antiochos et al., 2009; Barnes & Mawr 1976; Buchbinder et al, 2001; Chow et al., 1995; Fardet 
et al., 2009; Hill et al., 2001; Huang et al., 2009; Madan et al., 2009; Sigurgeirsson et al., 1992; 
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Stockton et al., 2001; Wakata et al., 2002; Williams Jr., 1959; Zantos et al., 1994). Although the 
frequency in case reports showed a very wide range from 3 to 60%, population-based cohort 
studies have demonstrate that cancer is detected in approximately 30% of DM and 15% of 
PM patients, and both groups have increased cancer risks compared with the general 
population (Table 1) (Zampieri et al., 2010). In recent years, relevant progress has been made 
in understanding the link between cancer and myositis, providing accurate description 
about their temporal relationship and the rationale about their pathophysiological 
mechanisms. 
 
Myositis patients 
number 
CAM 
number and (%) 
Reference 
DM PM DM PM  
392 396 94 (24) 58 (15) Sigurgeisson (14) 
618 914 198 (32) 137 (15) Hill (22) 
85 321 36 (42) 58 (18) Buchbinder (13) 
286 419 77 (27) 71 (17) Stockton (21) 
28 64 10 (36) 2 (3) Wakata (23) 
103 109 15 (15) 6 (6) Chinoy (55) 
1059 661 136 (13) 46 (7) Huang (25) 
121 NE 29 (24) NE Fardet (24) 
CAM: cancer associated myositis; DM: dermatomyositis; PM: polymyositis; NE: not evaluated. 
Table 1. Summary of reported CAM case series (adapted from Zampieri et al, 2010). 
3. Other neuromuscular paraneoplastic conditions 
Paraneoplastic syndromes (PS) are a group of conditions caused by an underlying immune 
response to cancer, thus not related to nutritional abnormalities, amyloid deposition, or 
adverse effects of treatment (Braik et al., 2010). Specific PS involving the neurological system 
(PNS) are rare, affecting 0,01% of patients with cancer and with overall incidence of about 1-
10 per 10,000. Only Lambert-Eaton myasthenic syndrome (LEMS) is relatively common, 
affecting 1% of patients with small cell lung cancer. The most common forms of PNS are the 
paraneoplastic sensory neuronopathy (3-7 per 1,000), the paraneoplastic encephalitis (3 per 
1,000), and the cerebellar degeneration (2 per 1,000). It is important to remark that these data 
may be underestimated because positive autoantibodies as a diagnostic criterium in these 
series were required (Graus & Dalmau, 2007; Honnorat & Antoine, 2007). 
PNS may affect the central nervous system (CNS), the neuromuscular junction, and the 
peripheral nervous system. Cognitive disorders, personality changes, ataxia, cranial nerve 
paralysis, weakness, numbness, and jerks are the main described symptoms. Clinical and 
laboratory features of the most frequent PNS are described in Table 2. Onconeuronal 
antibodies are the basis of the PNS pathogenesis, produced by an immune cross reaction 
between tumor and CNS cells  (Didelot & Honnorat, 2009). PNS may be classified into 
classical and non-classical disorders, being the first group more often associated with cancer 
(Table 3). 
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Paraneoplastic neurological syndromes 
PNS 
Clinical 
Presentation 
Associated 
cancer 
Antibodies 
LEMS 
Lower limbs 
proximal muscle 
weakness 
SCLC Anti-VGCC, anti-SOX 
Paraneoplastic 
cerebellar 
degeneration 
Ataxia, diplopia, 
dysphagia, 
dysartria 
Ovary, breast, 
SCLC, 
Hodgkin’s 
disease 
Anti-Yo, anti-Hu, anti-
CV2, anti-Ma, anti-Tr 
Opsoclonus-
myoclonus 
Dyskinetic shakes 
and myoclonic jerks 
of trunk and 
extremities 
Neuroblastoma, 
breast, lung 
Anti-Hu, anti-Ri 
Sensory 
neuronopathy 
Paresthesias/pain 
followed by ataxia 
SCLC Anti-Hu, anti-CV2 
Limbic encephalitis 
Mood changes, 
hallucinations, 
memory loss,  
seizures 
SCLC, testicular 
Anti-Hu, anti-CV2, anti 
–Ma, anti-amphiphysin 
PNS: Paraneoplastic neurological syndrome; LEMS: Lambert-Eaton myasthenic syndrome; SCLC: smal cell lung 
cancer. 
Table 2. Main features of most common PNS (modified from Braik et al., 2010; Didelot & 
Honnorat 2009; Graus et al., 2010). 
 
Paraneoplastic neurological syndromes 
Classical Non-classical 
Encephalomyelitis Optic neuritis 
Limbic encephalitis Cancer associated retinopathy 
Subacute cerebellar degeneration Melanoma associated retinopathy 
Opsoclonus-myoclonus Stiff person syndrome 
Subacute sensory neuronopathy Necrotising myelopathy 
Chronic gastrointestinal pseudo-
obstruction 
Motor neuron diseases 
Lambert-Eaton myasthenic syndrome 
Acute sensorimotor neuropathy : 
-  Guillain-Barré syndrome 
-  Brachial neuritis 
Dermatomyositis 
Subacute/chronic sensorimotor 
neuropathies 
 Neuropathy and paraproteinaemia 
 Neuropathy with vasculitis 
 Autonomic neuropathies 
 Myasthenia gravis 
 Acquired neuromyotonia 
 Acute necrotising myopathy 
PNS: Paraneoplastic neurological syndrome. 
Table 3. Classical and non-classical PNS (modified from Graus et al., 2004) 
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The presence of a PNS may offer the possibility of early diagnosis of cancer, since PNS 
occurs in up to 50 to 80% of cases without any other malignancy signs. Diagnosis should be 
made in 3 steps: 
1. To exclude other diagnosis: other conditions that may mimic PNS should be ruled out . 
These include: vascular diseases, connective tissue disorders, infections, nutritional 
disorders, adverse drug reactions, and exposure to toxins; 
2. To search for cancer: comprehensive medical history, physical examination, laboratory, 
and imaging techniques should be performed; 
3. To establish the diagnosis of PNS: this may require blood tests, imaging studies, 
electroencephalogram, nerve conduction studies, electromyography, and CSF 
examination. Onconeuronal antibodies may be positive in serum and/or CSF in 30% of 
patients (Braik et al., 2010). Table 4 summarizes the situations defined as definite or 
possible diagnosis of PNS. 
 
PNS Diagnostic Criteria 
Definite PNS Possible PNS 
1. Classical syndrome and cancer that develop 
within five years of the diagnosis of the 
neurological disorder. 
1. Classical syndrome, no 
onconeuronal antibodies, no cancer 
but at high risk to have an 
underlying tumour. 
2. Non-classical syndrome that resolves or 
significantly improves after cancer treatment 
without concomitant immunotherapy, provided 
that the syndrome is not susceptible to 
spontaneous remission. 
2. Neurological syndrome (classical 
or not) with partially characterized 
onconeuronal  antibodies and no 
cancer. 
3. Non-classical syndrome with onconeural 
antibodies (well characterized or not) and cancer 
that develop within five years of the diagnosis of 
the neurological disorder. 
3. Non-classical syndrome, no 
onconeuronal antibodies, and cancer 
present within two years of 
diagnosis. 
4. Neurological syndrome (classical or not) with 
well characterized onconeural antibodies (anti-
Hu, Yo, CV2, Ri, Ma2, or amphiphysin) and no 
cancer evidence. 
 
Well characterized onconeuronal antibodies included: Anti-Hu, Yo, CV2, Ri, Ma2, amphiphysin. Partially 
characterized onconeuronal antibodies: anti-Tr, ANNA3, PCA2, Zic4, mGluR1. 
Table 4. PNS diagnostic criteria. 
4. Myositis as paraneoplastic process 
Taken into account the aforementioned epidemiological and clinical data, as well as 
temporal relationship, it is important to note the possibility that many cases of the IIM 
represent autoimmune paraneoplastic processes related to solid tumor oncogenesis, 
indicating an immune-mediated destruction of muscle and skin as response to cancer 
antigens. This observation has been extensively described in the autoimmune PNS, in which 
severe, immune-mediated neuronal damage occurs in the setting of solid tumours whose 
primary sites are outside of the central nervous system (Albert & Darnell, 2004). The 
serological hallmark of this associated group of disorders is the association of stereotypical 
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autoantibody profiles with specific clinical phenotypes; furthermore, although the tumours 
are not neuronal in origin, they express high levels of protein antigens that are also highly 
expressed in neuronal tissue (Albert & Darnell, 2004; Furneaux et al., 1990). 
With regard to CAM, the underlying pathogenetic molecular mechanisms are still unknown, 
but some findings leading to better understanding have been reported. It is published that 
some tumours (breast, lung adenocarcinoma, hepatocellular carcinoma), but not the 
corresponding normal tissues, do express high levels of myositis autoantigens (Casciola-
Rosen et al., 2005); moreover, it has been reported that regenerating myoblasts overexpress 
myositis specific autoantigens in affected muscles from myositis patients, as well as tumor 
cells, indicating an immune response directed against cancer cells, cross-reacting with 
immature myoblasts in genetically predisposed individuals (Casciola-Rosen et al, 2005; 
Levine, 2006; Zampieri et al., 2010). 
5. Cancer chronopathology 
The temporal relationship between myopathy and cancer can widely vary. Malignancy may 
occur following the IIM diagnosis, be concurrently detected, or develop before. Despite this 
heterogeneous presentation, what is known is that cancer is usually recognized within 2-3 
years of diagnosis of IIM, with most cases within 12 months. 
6. Clinical, laboratory and pathological features 
Older age, male sex, severe skin manifestations, such as cutaneous necrosis, distal muscle 
involvement, as well as dysphagia or diaphragmatic involvement are more frequent among 
patients with CAM. Specific capillaroscopic patterns and refractory or recurrent disease 
have also been related to this association (Andras et al., 2008; Chen et al., 2001; Fardet et al., 
2009; Selva-O'Callaghan et al., 2010; Selva-O'Callaghan et al., 2002). Contrary to classical 
thought, case series suggest that cancer can also be present in the antisynthetase syndrome, 
indicating that the presence of antisynthetase antibodies does not rule out the CAM 
diagnosis (Buchbinder et al., 2001; Dugar et al., 2010; Legault et al., 2008; Mileti et al., 2009). 
Among the laboratory parameters, the role of raised creatine kinase is controversial. It can 
be normal or slightly elevated, but highly elevations in CAM have been reported. Low levels 
of complement factor 4 have been published as a risk factor to occult cancer, whereas low 
baseline lymphocyte count and the presence of antinuclear antibodies have been reported as 
a protective features (Andras et al., 2008; Fardet et al., 2009). 
Although no definite pathological features have been reported in CAM,  the presence of a 
necrotizing myopathy, type of myopathy with severe necrosis with almost complete absence 
of inflammation (Amato & Barohn 2009; Dalakas 2011; Wegener et al., 2010), a higher 
number of fibers with internally located nuclei (Zampieri et al., 2010), and the identification 
of the neural cell adhesion molecules (Jensen & Berthold 2007; Zampieri et al., 2010) has 
been associated with cancer. 
7. Screening approach 
There is no doubt that an individually tailored screening for cancer in IIM patients is 
recommended according to age, sex, ethnicity, and subset of IIM, although, to date, there are 
no evidence-based recommendations. Moreover, continued surveillance is needed during 
the follow-up since cancer risk remains elevated for years after the diagnosis of IIM. 
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7.1 Standard work-up 
An advisable approach include a careful history-taking and physical examination, blood 
tests with full blood count, erythrocyte sedimentation rate, routine biochemistry, chest RX, 
urinary cytology, fecal occult test, whole-body computed tomography scanning, and 
mammography, gynaecological examination, and pelvic ultrasonography in female patients, 
as well as prostate examination in men. 
7.2 Immunoserological testing 
Autoantibodies, including myositis-associated (MAA) and myositis-specific (MSA), are 
found in about 40% of patients with IIM. MAA include PM-Scl, Ku, snRNP, Ro60/SSA, 
Ro52, and La/SSB. MSA antibodies are highly specific for IIM, defining clinical and 
immunogenetics subsets of patients that may show different response to therapy and 
prognosis (Danko et al., 2009, 21; Love et al., 1991, 70; Rider & Miller, 2011), such as 
antisynthetases, anti-signal recognition particle (SRP), anti-Mi-2, and recently, anti-155/140. 
Classically, a negative association between the presence of antisynthetase antibodies was 
accepted, but, in recent years, scarce cases and small series of patients with antisynthetase 
syndrome and cancer have been published (Dugar et al., 2010; Legault et al., 2008; Mileti et 
al., 2009). Cancer relevance of anti-Mi-2 antibodies is unknown since only two studies have 
explored this issue with opposite results (Hengstman et al., 2006; O'Hanlon et al., 2006). 
Anti p155, autoantibody against a 155kDa protein identified as transcriptional intermediary 
factor 1-γ (TIF1-γ), was first defined by Targoff in 2006 (Targoff et al., 2006) as an 
autoantibody associated with DM and CAM. The association between antip155 and 
malignancy has subsequently been confirmed by other investigators, reinforcing this link 
(Table 5) (Chinoy et al., 2009, 21; Fujikawa et al., 2009, 38; Gunawardena et al., 2008, 47; Kaji 
et al., 2007; Trallero-Araguas et al., 2010). The interest of antip155 autoantibody lies in its 
high negative predictive value or, in other words, its capacity to reasonable rule out the 
presence of occult cancer in patients with DM. An unpublished meta-analysis of the 
reported studies on this subject performed by the authors (Selva-O'Callaghan et al., 2010) to 
determine the overall accuracy of this autoantibody in DM reveals a specificity of 89% [95% 
CI 85-93] and sensitivity of 70% [95% CI 56-82], with a negative predictive value of 93% and 
a diagnostic odds ratio of 18 [95% 8-40], this means a 18-fold higher risk of cancer in patients 
with positive testing to p155. 
 
N CAM (Ab)* 
No CAM 
(Ab)** 
NPV PPV Reference 
45 6 (6) 39 (8) 100 42,9 Targoff et al. 
20 3 (3) 17 (3) 100 50 
Gunawardena 
et al. 
52 10 (5) 42 (2) 88,9 71,4 Kaji et al. 
103 15 (8) 88 (11) 91,6 42,1 Chinoy et al. 
30 5 (5) 25 (0) 100 100 Fujikawa et al. 
65 14 (10) 51 (5) 92 66,7 
Trallero-
Araguás et al. 
Ab, antibody; CAM, cancer-associated myositis; N, number of patients; NPV, negative predictive value; PPV, 
positive predictive value. 
*Number of patients with CAM (number of those who are antibody-positive). 
**Number of patients without CAM (number of those who are antibody-positive). 
Table 5. Antip155 and CAM in DM (Selva-O'Callaghan et al., 2010). 
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7.3 Positron emission tomography 
Positron emission tomography (PET) using [18F] fluorodeoxyglucose (FDG), and more 
recently, combined FDG-PET/computed tomography (FDG-PET/CT), is one of the most 
sensitive imaging techniques to diagnose malignant disorders, successfully used in other 
paraneoplastic conditions (Hadjivassiliou et al., 2009; Patel et al., 2008). Our group 
performed a multicenter, prospective study including 55 consecutive DM/PM patients, 
diagnosed over a three-year period, to compare conventional cancer screening as mentioned 
above, with whole-body FDG-PET/CT (Selva-O'Callaghan et al., 2010). A sensitivity and 
specificity of both approaches were similar in excluding an occult malignancy, as well as 
false-positive and false-negative results; furthermore, a combination of two methods did not 
significantly increase the predictive value. From these results we suggest that FDG-PET/CT 
may be a good alternative to broad conventional malignancy screening, with the added 
advantage that a single imaging technique is more convenient for both the patient and the 
physician. 
8. Clinical practice 
Given the mentioned results of immunological (antip155 antibodies) and imaging (FDG-
PET/CT) tests, we propose a reasonable approach for ruling out occult cancer in myositis 
(Fig.1) (Selva-O'Callaghan et al., 2010).  
 
 
 
 
DM: dermatomyositis; PM: polymyositis; sIBM: sporadic inclusion body myositis, PET: positron emission 
tomography; CT: computed tomography. 
Fig. 1. Algorithm for diagnosis of occult cancer in inflammatory myopathies (Selva-
O'Callaghan et al., 2010). 
 
MYOSITIS 
 
DM 
 
PM 
 
sIBM 
No 
screening 
PET/CT 
once at 
diagnosis 
PET/CT 
once at 
diagnosis 
 
p155 (+) 
 
p155 (-) 
PET/CT 
yearly for 
3-5 years 
PET/CT 
once at 
diagnosis 
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After unequivocal diagnosis of IIM (especially in PM), a careful history-taking and physical 
examination, and standard laboratory testing should be performed in all patients. 
 In IBM patients, given that the risk of cancer is extremely low, no screening or a single 
FDG-PET/CT is recommended. 
 In PM patients, a population with moderate risk, yearly FDG-PET/CT for 3-5 years 
would be reasonable. Antip155 test is not useful because it is rarely present in this IIM 
subset. 
 In DM patients, we recommend an initial antip155 determination. When the test is 
negative, a single FDG-PET/CT would be enough to preclude malignancy. However, in 
patients with DM and positive antip155 test, yearly FDG-PET/CT for, at least, 3-5 years 
is warranted. 
Considering that test for detecting antip155 antibodies and FDG-PET/CT are available at 
only a few hospitals, as well as the high cost of the imaging technique, we propose a more 
straightforward alternative guideline to rule out cancer in myositis patients (Fig.2): 
 In IBM patients, no screening or a single standard work-up (see above). 
 In PM patients, yearly standard work-up for 3-5 years. 
 In DM patients, yearly standard work-up for 3-5 years. 
 
 
DM: dermatomyositis; PM: polymyositis; sIBM: sporadic inclusion body myositis. 
Fig. 2. Alternative algorithm for diagnosis of occult cancer in inflammatory myopathies. 
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